3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
2
Neoplasms
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Thalidomide
2
omburtamab I-131
1
entinostat
1
carboxyamido-triazole
1
belzutifan
1
Radiotherapy, Image-Guided
1
Paclitaxel
1
Nivolumab
1
Genistein
1
Fentanyl
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cyclophosphamide
1
CLR1404
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
Genistein
×
Genitourinary
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts